Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

J T Larsen; S K Kumar; A Dispenzieri; R A Kyle; J A Katzmann; S V Rajkumar

doi:10.1038/leu.2012.296

journal article Oct 16, 2012

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

J T Larsen S K Kumar A Dispenzieri R A Kyle J A Katzmann S V Rajkumar

Leukemia Vol. 27 No. 4 pp. 941-946 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/leu.2012.296

Topics

No keywords indexed for this article. Browse by subject →

References

25

[1]

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

R A Kyle, B G M Durie, S V Rajkumar et al.

Leukemia 2010 10.1038/leu.2010.60

[2]

Group TIMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757. 10.1046/j.1365-2141.2003.04355.x

[3]

Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775–779. 10.1038/sj.leu.2402866

[4]

Barlogie B, van Rhee F, Shaughnessy JD, Epstein J, Yaccoby S, Pineda-Roman M et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008; 112: 3122–3125. 10.1182/blood-2008-06-164228

[5]

Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008; 113: 1588–1595. 10.1002/cncr.23783

[6]

Rajkumar SV, Merlini G, San Miguel JF . Redefining myeloma. Nat Rev Clin Oncol 2012; 9: 494–496. 10.1038/nrclinonc.2012.128

[7]

Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582–2590. 10.1056/nejmoa070389

[8]

A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance

Robert A. Kyle, Terry M. Therneau, S. Vincent Rajkumar et al.

New England Journal of Medicine 2002 10.1056/nejmoa01133202

[9]

Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586–2592. 10.1182/blood-2007-05-088443

[10]

Rajkumar SV, Larson D, Kyle RA . Diagnosis of smoldering multiple myeloma. N Engl J Med 2011; 365: 474–475. 10.1056/nejmc1106428

[11]

Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111: 785–789. 10.1182/blood-2007-08-108357

[12]

Rajkumar SV, Kyle RA, Therneau TM, Clark RJ, Bradwell AR, Melton LJ et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol 2004; 127: 308–310. 10.1111/j.1365-2141.2004.05169.x

[13]

Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008; 22: 1933–1937. 10.1038/leu.2008.171

[14]

Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78–84. 10.1046/j.1365-2141.2003.04433.x

[15]

Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA . Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005; 51: 878–881. 10.1373/clinchem.2004.046870

[16]

Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437–1444. 10.1093/clinchem/48.9.1437

[17]

Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT . Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489–491. 10.1016/s0140-6736(03)12457-9

[18]

Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR . Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900–2902. 10.1182/blood.v97.9.2900

[19]

van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827–832. 10.1182/blood-2007-01-067728

[20]

Waxman AJ, Kuehl M, Balakumaran A, Weiss B, Landgren O . Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future. Clin Lymphoma Myeloma Leuk 2010; 10: 248–257. 10.3816/clml.2010.n.053

[21]

Alexanian R, Barlogie B, Dixon D . Prognosis of asymptomatic multiple myeloma. Arch Intern Med 1988; 148: 1963–1965. 10.1001/archinte.1988.00380090051014

[22]

Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009; 84: 114–122. 10.4065/84.2.114

[23]

Golombick T, Diamond TH, Manoharan A, Ramakrishna R . Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4 g study and an open-label 8 g extension study. Am J Hematol 2012; 87: 455–460. 10.1002/ajh.23159

[24]

Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412–5417. 10.1182/blood-2008-12-194241

[25]

Mateos M, Lopez-Corral L, Hernandez M, Giraldo P, De la Rubia J, De Arriba F et al. Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: a phase III, randomized, multicenter trial based on lenalidomide-dexamethasone (Len-Dex) as induction therapy followed by maintenance therapy with Len alone vs no treatment. Blood (ASH Annual Meeting Abstracts) 2011; 118: 3996.

Metrics

201

Citations

25

References

Details

Published: Oct 16, 2012
Vol/Issue: 27(4)
Pages: 941-946
License: View

Authors

Cite This Article

J T Larsen, S K Kumar, A Dispenzieri, et al. (2012). Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia, 27(4), 941-946. https://doi.org/10.1038/leu.2012.296

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

You May Also Like